News
-
Noveome Biotherapeutics has signed a research and development agreement with Walter Reed Army Institute of Research (WRAIR) regarding preclinical studies of an intranasal formulation of Noveome’s ST266 secretome, the company said. Under the agreement, WRAIR… Read more . . .
-
Ovoca Bio announced that it has initiated a Phase 2 study of its BP-101 intranasal synthetic peptide for the treatment of hypoactive sexual desire disorder (HSDD). The dose ranging study, which will take place in… Read more . . .
-
According to Pulmotect, the US Department of Defense has provided a grant worth up to $6 million for the completion of two Phase-2 clinical trials of the company’s PUL-042 immunostimulant inhalation solution for the prevention… Read more . . .
-
AIM ImmunoTech announced that the Centre for Human Drug Research (CHDR) will conduct a Phase 1 study of an intranasal formulation of the company’s Ampligen rintatolimod, which the company wants to develop for the treatment… Read more . . .
-
According to AstraZeneca, China’s National Medical Products Administration (NMPA) has approved Symbicort Turbuhaler budesonide / formoterol as a reliever inhaler for the treatment of symptoms of mild asthma in patients age 12 and older. Symbicort Turbuhaler was… Read more . . .
-
United Therapeutics announced that its BREEZE study has demonstrated that patients with pulmonary arterial hypertension (PAH) who use Tyvaso treprostinil inhalation solution can safely switch to the Tyvaso treprostinil DPI. The company also announced that… Read more . . .
-
University of St Andrews spin out Pneumagen said that it has raised £2.5 million for clinical development of its Neumifil intranasal carbohydrate binding module (mCBM) for the prevention and treatment of respiratory viruses, including flu,… Read more . . .
-
Meissa Vaccines said that it has started dosing participants in its Phase 2 trial of MV-012-968 intranasal live attenuated vaccine candidate against respiratory syncytial virus (RSV). MV-012-968 is based on Meissa’s AttenuBlock platform, which it… Read more . . .
-
According to Impel NeuroPharma, the FDA has accepted the company’s 5O5(b)(2) NDA for its INP104 intranasal dihydroergotamine mesylate (DHE) for the treatment of migraine headaches and has set a PDUFA goal date of September 6,… Read more . . .
-
Synairgen said that the first patient has been dosed in the Phase 3 SG018 trial of its SNG001 inhaled interferon beta-1a in hospitalized COVID-19 patients, with the SG018 study expected to enroll 610 COVID-19 patients… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.